Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lytix Biopharma AS's share price for the quarter that ended in Mar. 2026 was kr10.3. Lytix Biopharma AS's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 76.90 Mil. Therefore, Lytix Biopharma AS's market cap for the quarter that ended in Mar. 2026 was kr792.07 Mil.
Lytix Biopharma AS's quarterly market cap
increased
from Sep. 2025 (kr484.66 Mil) to Dec. 2025 (kr674.43 Mil) and
increased
from Dec. 2025 (kr674.43 Mil) to Mar. 2026 (kr792.07 Mil).
Lytix Biopharma AS's annual market cap
increased
from Dec. 2023 (kr194.73 Mil) to Dec. 2024 (kr400.78 Mil) and
increased
from Dec. 2024 (kr400.78 Mil) to Dec. 2025 (kr674.43 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lytix Biopharma AS's Enterprise Value for Today is kr581.63 Mil.
Lytix Biopharma AS (OSL:LYTIX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lytix Biopharma AS Market Cap Related Terms
Lytix Biopharma AS Market Cap Historical Data
* Premium members only.
The historical data trend for Lytix Biopharma AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:LYTIX vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Lytix Biopharma AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lytix Biopharma AS Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Lytix Biopharma AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lytix Biopharma AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lytix Biopharma AS (OSL:LYTIX) has a Market Cap of kr699.79 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lytix Biopharma AS and its competitors. According to the industry distribution chart, Lytix Biopharma AS ranks #811 out of 1423 companies in the Biotechnology industry, placing it in the top 57%.
Is Lytix Biopharma AS's Market Cap too high?
Lytix Biopharma AS's current Market Cap is kr699.79 Mil. Based on the distribution chart, Lytix Biopharma AS ranks #811 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lytix Biopharma AS has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lytix Biopharma AS ranks #811 out of 1423 companies for Market Cap. This places Lytix Biopharma AS in the lower half of its industry. The industry median Market Cap is 111.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lytix Biopharma AS and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lytix Biopharma AS's current Market Cap is kr699.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr9.10 — trading 5252.9% above its estimated fair value. The current Market Cap is kr699.79 Mil. Lytix Biopharma AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Market Cap is kr699.79 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?
Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued.
The current stock price of kr9.10 is trading 5252.9% above its estimated GF Value™ of kr0.17.
GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.
Key valuation signals for OSL:LYTIX:
Market Cap: kr699.79 Mil
GF Value™: kr0.17 vs. price of kr9.10 (5252.9% above fair value)
No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
28GF Score
Get the complete analysis for OSL:LYTIX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:LYTIX has been successfully added to your 
